Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.8M | $20.6M | $26.4M | $27.3M | $9.58M | $27.0M | $44.5M | $24.4M | $41.8M | $27.5M |
| Revenue growth | — | 39.0% | 28.4% | 3.2% | -64.9% | 182.4% | 64.7% | -45.2% | 71.3% | -34.3% |
| Gross profit | $9.85M | $13.8M | $16.9M | $17.6M | $5.25M | $17.0M | $29.6M | $14.1M | $24.4M | $11.9M |
| Gross margin | 66.5% | 67.0% | 64.0% | 64.4% | 54.8% | 62.8% | 66.5% | 57.6% | 58.4% | 43.2% |
| Operating income | -$363K | -$3.72M | -$2.01M | -$1.97M | -$8.23M | $4.12M | $14.8M | -$382K | $8.09M | -$10.3M |
| Operating margin | -2.5% | -18.1% | -7.6% | -7.2% | -86.0% | 15.2% | 33.3% | -1.6% | 19.4% | -37.5% |
| Net income | -$346K | -$3.71M | -$2.02M | -$1.70M | -$6.84M | $4.12M | $24.2M | $485K | $6.65M | -$7.72M |
| Net margin | -2.3% | -18.0% | -7.7% | -6.2% | -71.4% | 15.2% | 54.4% | 2.0% | 15.9% | -28.1% |
| EPS (diluted) | -$0.03 | -$0.28 | -$0.14 | -$0.10 | -$0.42 | $0.25 | $1.46 | $0.03 | $0.41 | -$0.47 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$851K | -$3.06M | -$8.56M | -$2.11M | -$434K | -$286K | -$1.41M | -$2.15M | -$831K | $528K |
| Capital expenditures | $286K | $288K | $855K | $401K | $359K | $128K | $159K | $229K | $276K | $196K |
| Free cash flow | -$1.14M | -$3.34M | -$9.42M | -$2.51M | -$793K | -$414K | -$1.57M | -$2.37M | -$1.11M | $332K |
| Share buybacks | — | — | — | — | — | — | $3.00M | $27.0K | — | $300K |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5.04M | $10.1M | $12.5M | $8.10M | $14.9M | $14.5M | $25.5M | $23.1M | $22.1M | $22.1M |
| Total assets | $18.9M | $18.8M | $33.3M | $36.9M | $28.0M | $32.2M | $56.7M | $53.7M | $62.2M | $53.0M |
| Total liabilities | $3.67M | $7.15M | $6.79M | $8.92M | $6.51M | $6.22M | $8.67M | $4.87M | $6.34M | $4.94M |
| Shareholders' equity | $15.3M | $11.7M | $26.5M | $28.0M | $21.5M | $26.0M | $48.1M | $48.8M | $55.8M | $48.1M |
| Retained earnings | -$7.79M | -$11.5M | -$13.5M | -$15.2M | -$22.1M | -$17.9M | $6.30M | $6.79M | $13.4M | $5.71M |
| Shares (wtd avg diluted) | 13.5M | 13.5M | 16.1M | 16.5M | 16.4M | 16.5M | 16.6M | 16.3M | 16.4M | 16.3M |
Every figure is extracted from Sensus Healthcare, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.